Search results for "Relative risk"

showing 10 items of 303 documents

Prognostic implications of extranodal extension in node-positive squamous cell carcinoma of the vulva: A systematic review and meta-analysis

2016

Squamous cell carcinoma (SCC) of the vulva is the fourth most common gynecological cancer, usually staged with the TNM or FIGO systems. Since 2009, FIGO staging has taken the extranodal extension (ENE) of lymph node metastases into account. ENE is defined as the spread of a lymph node metastasis into surrounding soft tissue. Although the TNM and FIGO systems acknowledge the importance of ENE in SCC, no comprehensive studies have analyzed the prognostic impact of this parameter. We therefore queried the PubMed and SCOPUS databases from their inception up until 04/01/2015, adopting no language restrictions: all prospective studies reporting on prognostic parameters in patients with vulvar SCC…

Oncologymedicine.medical_specialtyExtranodal metastasisVulva03 medical and health sciences0302 clinical medicineInternal medicineExtranodal extensionmedicineHumans030212 general & internal medicineProspective cohort studyLymph nodeGynecologyVulvar neoplasmVulvar NeoplasmsVulvar cancerbusiness.industryENE; Extranodal extension; Extranodal metastasis; Vulvar cancer; Oncology; SurgeryHazard ratioVulvar cancerENE; Extranodal extension; Extranodal metastasis; Vulvar cancermedicine.diseasePrognosisExtranodal metastasimedicine.anatomical_structureOncology030220 oncology & carcinogenesisMeta-analysisRelative riskCarcinoma Squamous CellENEFemaleSurgeryLymph Nodesbusiness
researchProduct

Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis

2018

Extranodal extension (ENE) of nodal metastasis is defined as the extension of metastatic cells through the nodal capsule into the perinodal tissue. This morphological parameter, recently proposed as an important prognostic factor in different types of malignancy, has not been included in the TNM staging system for non-small cell lung cancer (NSCLC). In this systematic review with meta-analysis, we weighted the prognostic role of ENE in patients with lymph node-positive NSCLC. Two independent authors searched SCOPUS and PubMed through 28 February 2017. Prospective and retrospective studies on NSCLC, comparing patients with presence of ENE (ENE+) ENE+) vs. only intranodal extension (ENE–) and…

Oncologymedicine.medical_specialtyLung NeoplasmsExtracapsular; Extranodal; Lung cancer; Metastasis; NSCLC; PrognosisTNM staging systemNSCLCMalignancyMetastasisPathology and Forensic MedicineMetastasis03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungInternal medicinemedicine030212 general & internal medicineLung cancerMolecular BiologyEne reactionLung cancer . NSCLC . Prognosis . Extranodal . Extracapsular . MetastasisExtracapsularbusiness.industryHazard ratioRetrospective cohort studyCell BiologyGeneral MedicinePrognosismedicine.diseaseLymphatic Metastasis030220 oncology & carcinogenesisRelative riskExtranodalLymph NodesLung cancerNeoplasm Recurrence Localbusiness
researchProduct

Hematopoietic and lymphatic cancers in patients with periodontitis : a systematic review and meta-analysis

2019

Background Numerous studies have explored the correlation of periodontal disease (PD) with risk of hematopoietic and lymphatic cancers, but the findings were inconsistent. Therefore, we did a meta-analysis to ascertain the correlation of PD with risk of incident hematopoietic and lymphatic cancers. Material and Methods The authors searched relevant studies in databases (PubMed, Web of Science, and MEDLINE). The summary relative risk (RR) along with 95% confidence interval (CI) was calculated by use of random or fixed effects models. Results Six studies were included in qualitative synthesis. The pooled analysis revealed that PD was significantly associated with an increased risk of hematopo…

Oncologymedicine.medical_specialtyPopulationMEDLINEReview03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineNeoplasmsmedicineHumansPeriodontologyRisk factoreducationPeriodontitisGeneral DentistryPeriodontitiseducation.field_of_studybusiness.industryHematopoietic Stem Cell Transplantation030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Confidence intervalLymphatic systemOtorhinolaryngologyMeta-analysisRelative riskUNESCO::CIENCIAS MÉDICASSurgerybusiness
researchProduct


 Consistency and Proportionality in Policy Decision-Making in Blood Safety: the Case for an All-Apheresis Platelet Supply in Germany

2013

SUMMARY Recently, German investigators presented the first mathematical model finding a significant increase in the risk of HIV, HCV, and HBV transmission when pools of 4 whole-blood-derived buffy-coat platelets, rather than 1 singledonor (apheresis) component, are used to provide one platelet dose. Based, in both cases, on mathematical models employing the incidence/window-period method, the relative risk of transmission from pooled versus apheresis platelets (2.2 or 2.75 for HIV, 2.7 or 3.375 for HCV, and 3.2 or 4.0 for HBV, with pools of 4 or 5 concentrates, respectively) is similar to the difference in risk before (versus after) introduction of HIV-1 and HCV RNA screening. The absolute …

Oncologymedicine.medical_specialtybusiness.industryHuman immunodeficiency virus (HIV)Viral transmissionvirus diseasesPathogen reductionmedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyPolicy decisionInternal medicineRelative riskImmunologymedicineBlood safetyPlateletbusinessModel findingClinical Laboratory
researchProduct

From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters

2006

Recently, chemoprevention trials have demonstrated the efficacy of preventive medical treatment (PMT) in reducing breast cancer (BC) detection rates in at-risk affected and unaffected women selected according to clinical and/or familial risk criteria, particularly with the use of tamoxifen (TAM). Major concerns limiting the routine use of TAM are the questionable benefit/risk ratio and poor patient compliance, which justify the studies undertaken to determine the efficacy of aromatase inhibitors (AIs) with respect to TAM. Issues such as therapy duration, impact on survival, incidence of side-effects and which subsets benefit most from treatment, still remain unsolved. Therefore, only ER+ BC…

Oncologymedicine.medical_specialtymedicine.medical_treatmentGenes BRCA2Genes BRCA1Breast NeoplasmsBreast cancerRisk FactorsInternal medicinemedicineHumansGenetic Predisposition to DiseaseAromataseskin and connective tissue diseasesbiologybusiness.industryIncidence (epidemiology)Estrogen AntagonistsHematologymedicine.diseaseClinical trialTamoxifenOncologyChemotherapy AdjuvantRelative riskbiology.proteinHormonal therapyFemalebusinessAdjuvantTamoxifenmedicine.drugAnnals of Oncology
researchProduct

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selecte…

2021

BACKGROUND: The advent of immuno-oncology (IO) represented a breakthrough in non-small cell lung cancer (NSCLC) therapy over the last few years. However, establishing the optimal therapeutic options among programmed death-ligand 1 (PD-L1) selected subgroups still addresses an unmet need in the clinical setting. METHODS: We performed a systematic review and finally included eleven first-line randomized controlled trials to compare efficacy and safety outcomes among first-line IO treatment strategies versus standard platinum-based chemotherapy (CT) according to PD-L1 expression level (<1%, 1–49%, ≥50%). Pooled hazard ratios (HRs) and risk ratios (RRs) for progression-free survival (PFS), over…

Oncologymedicine.medical_specialtyprogrammed death-1/cytotoxic T-lymphocyte antigen 4 inhibitors (PD-1/CTLA-4 inhibitors)combined modality therapybusiness.industryHazard ratioCombined modality therapy; Immunotherapy; Meta-analysis; Non-small cell lung cancer (NSCLC); Programmed death-1/cytotoxic T-lymphocyte antigen 4 inhibitors (PD-1/CTLA-4 inhibitors)non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NSCLC)medicine.diseaselaw.inventionDiscontinuationmeta-analysisOncologyRandomized controlled triallawRelative riskInternal medicineMeta-analysisMedicineOriginal ArticleimmunotherapybusinessLung cancerAdverse effect
researchProduct

Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure : the DIANA study

2020

© 2020 The Author(s).

OriginalDELPHI METHODCritical Care and Intensive Care MedicineGUIDELINESlaw.invention0302 clinical medicineAnti-Infective Agents[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawEpidemiologyMedicine and Health SciencesAntimicrobial de-escalationEPIDEMIOLOGYComputingMilieux_MISCELLANEOUS[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesVentilator-associated pneumoniaIntensive care unitAnti-Bacterial Agents3. Good healthIntensive Care UnitsSTEWARDSHIP PROGRAM[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCohortAntimicrobial de-escalation; Bacterial infection; Clinical cure; Empirical therapy; Intensive care unit;Clinical cureAntimicrobial de-escalation; Bacterial infection; Clinical cure; Empirical therapy; Intensive care unitAdultmedicine.medical_specialtyCombination therapyCritical IllnessANTIBIOTIC-THERAPYNO03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemBETA-LACTAMInternal medicineSettore MED/41 - ANESTESIOLOGIAmedicineHumans[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyIntensive care unitVENTILATOR-ASSOCIATED PNEUMONIAbusiness.industrySEPTIC SHOCKR-PACKAGEbacterial infectionIntensive care unit.030208 emergency & critical care medicinemedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyEmpirical therapyDiscontinuationSEVERE SEPSISlnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Carbapenems030228 respiratory systemRelative riskBacterial infectionbusinessDe-escalation
researchProduct

Familial hypercholesterolaemia: A global call to arms

2015

Familial Hypercholesterolaemia (FH) is the commonest autosomal co-dominantly inherited condition affecting man. It is caused by mutation in one of three genes, encoding the low-density lipoprotein (LDL) receptor, or the gene for apolipoprotein B (which is the major protein component of the LDL particle), or in the gene coding for PCSK9 (which is involved in the degradation of the LDL-receptor during its cellular recycling). These mutations result in impaired LDL metabolism, leading to life-long elevations in LDL-cholesterol (LDL-C) and development of premature atherosclerotic cardiovascular disease (ASCVD) [1], [2] and [3]. If left untreated, the relative risk of premature coronary artery d…

PathologyApolipoprotein BDisease030204 cardiovascular system & hematologymedicine.disease_causeGlobal HealthDISEASEDoenças Cardio e Cérebro-vasculares0302 clinical medicineHyperlipoproteinemia Type IISocieties MedicalRISK0303 health sciencesMutationbiology3. Good healthPREVALENCEEuropelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineFamilial hypercholesterolaemiaLife Sciences & Biomedicinemedicine.medical_specialtyHeterozygote1102 Cardiovascular Medicine And HaematologyHyperlipoproteinemia Type II03 medical and health sciencesInternal medicinemedicineHumans030304 developmental biologyScience & Technologybusiness.industryGUIDANCEPCSK9Heterozygote advantage1103 Clinical SciencesEndocrinologyPeripheral Vascular DiseaseCardiovascular System & HematologyReceptors LDLRECEPTORES DE LIPOPROTEÍNASRelative riskMutationbiology.proteinCardiovascular System & CardiologyFamilial HypercholesterolaemiabusinessCLINICIANLipoprotein
researchProduct

Maternal complications in pregnancy and wheezing in early childhood: a pooled analysis of 14 birth cohorts

2015

Background: Evidence on the effect of maternal complications in pregnancy on wheezing in offspring is still insufficient. Methods: A pooled analysis was performed on individual participant data from fourteen European birth cohorts to assess the relationship between several maternal pregnancy complications and wheezing symptoms in the offspring. Exposures of interest included hypertension and preeclampsia, diabetes, as well as pre-pregnancy overweight (body mass index between 25 and 29.9) and obesity (body mass index >= 30) compared with normal weight (body mass index between 18.5 and 24.9). Outcomes included both ever and recurrent wheezing from birth up to 12-24 months of age. Cohort-speci…

PediatricsPRESCHOOL-CHILDRENEpidemiologyPREPREGNANCY OBESITYINFANTSOverweightDISEASEBody Mass IndexPregnancyRisk FactorsGestational diabetes; Obesity; Overweight; Pre-eclampsia; Pregnancy induced hypertension; Birth Weight; Body Mass Index; Diabetes Gestational; Female; Humans; Hypertension; Obesity; Overweight; Pre-Eclampsia; Pregnancy; Pregnancy Complications; Prevalence; Risk Factors; Respiratory Sounds; Epidemiology; Medicine (all)PrevalenceBirth WeightGestational diabetes2. Zero hungerGESTATIONAL WEIGHT-GAINRISKMedicine (all)DiabetesGeneral Medicine3. Good healthGestational diabetesGestational diabeteGestationalHypertensionGROWTHGeneration RFemalemedicine.symptommedicine.medical_specialtyOffspringBirth weightEARLY-LIFEmedicineHumansPregnancy induced hypertensionObesityRespiratory SoundsPregnancyOVERWEIGHTbusiness.industryASTHMA SYMPTOMSOverweightmedicine.diseasePregnancy ComplicationsDiabetes GestationalRelative riskGENERATION RbusinessBody mass indexPre-eclampsiaInternational Journal of Epidemiology
researchProduct

Global, regional, and national levels and causes of maternal mortality during 1990-2013: A systematic analysis for the Global Burden of Disease Study…

2014

BACKGROUND: The fifth Millennium Development Goal (MDG 5) established the goal of a 75% reduction in the maternal mortality ratio (MMR; number of maternal deaths per 100,000 livebirths) between 1990 and 2015. We aimed to measure levels and track trends in maternal mortality, the key causes contributing to maternal death, and timing of maternal death with respect to delivery.METHODS: We used robust statistical methods including the Cause of Death Ensemble model (CODEm) to analyse a database of data for 7065 site-years and estimate the number of maternal deaths from all causes in 188 countries between 1990 and 2013. We estimated the number of pregnancy-related deaths caused by HIV on the basi…

PediatricsTime FactorsNutrition and Diseasehiv-infectionimmunodeficiency virus-1 infectionperipartum cardiomyopathyPoison controlHIV InfectionsIMMUNODEFICIENCY VIRUS-1 INFECTIONSocioeconomic FactorGlobal Health0302 clinical medicinePERIPARTUM CARDIOMYOPATHYpregnancy-related mortalityRisk FactorsPregnancyVoeding en ZiekteCause of DeathGlobal healthHIV Infection030212 general & internal medicinePregnancy Complications Infectious10. No inequalityCause of death030219 obstetrics & reproductive medicinesouth-africaMedicine (all)1. No povertyWOMENPREGNANCY-RELATED MORTALITYhealth initiativesGeneral MedicineSOUTH-AFRICA3. Good healthMaternal MortalityWorld HealthCHILD SURVIVALFemaleMaternal deathwomenHumanmedicine.medical_specialtyTime FactorDEATHSchild survivalArticleadult mortality03 medical and health sciencesAge DistributionHEALTH INITIATIVESSDG 3 - Good Health and Well-beingHIV-INFECTIONADULT MORTALITYInjury preventionmedicineOrganizational ObjectivesOrganizational ObjectiveHumansVLAGPregnancyModels Statisticalbusiness.industryRisk Factormedicine.diseasedeathsStandardized mortality ratioSocioeconomic FactorsRelative riskPregnancy Complications InfectioubusinessDemography
researchProduct